Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Change in Inventory (2021 - 2025)

Historic Change in Inventory for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Q3 2025 value amounting to $1.2 million.

  • Mirum Pharmaceuticals' Change in Inventory rose 2834.99% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year increase of 27093.02%. This contributed to the annual value of $3.2 million for FY2024, which is 22505.13% up from last year.
  • According to the latest figures from Q3 2025, Mirum Pharmaceuticals' Change in Inventory is $1.2 million, which was up 2834.99% from $2.3 million recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' Change in Inventory ranged from a high of $2.8 million in Q3 2022 and a low of -$1.2 million during Q4 2023
  • Moreover, its 5-year median value for Change in Inventory was $933500.0 (2024), whereas its average is $890562.5.
  • Per our database at Business Quant, Mirum Pharmaceuticals' Change in Inventory plummeted by 22080.81% in 2022 and then skyrocketed by 106119.4% in 2023.
  • Over the past 5 years, Mirum Pharmaceuticals' Change in Inventory (Quarter) stood at $495000.0 in 2021, then crashed by 220.81% to -$598000.0 in 2022, then crashed by 106.02% to -$1.2 million in 2023, then surged by 117.37% to $214000.0 in 2024, then skyrocketed by 441.59% to $1.2 million in 2025.
  • Its Change in Inventory stands at $1.2 million for Q3 2025, versus $2.3 million for Q2 2025 and $2.7 million for Q1 2025.